Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G17DT vs Gemcitabine in advanced pancreatic cancer
NCT03200821Phase 3Completed
- Sponsor
- Cancer Advances, Inc.
- Start
- Aug 2000
- Primary completion
- Sep 2001
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of G17DT immunogen in pancreatic adenocarcinoma (PDAC), sponsored by Cancer Advances, Inc.. Started Aug 2000; status: completed.
02
Drugs
G17DT immunogen
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03200821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03200821.